Isu Abxis Licenses Pabagal Technology for Rare Disease Treatment to Russian Pharmaceutical Company

[Asia Economy Reporter Ji Yeon-jin] Isu Abxis announced on the 26th that it has signed a technology transfer agreement for the rare disease treatment drug 'Pavagal' with the Russian pharmaceutical company Petrovax (NPO Petrovax Pharm).

This technology transfer agreement includes an upfront payment, milestones, and royalties based on sales. Specific contract details will remain confidential by mutual agreement between the two companies to ensure smooth business operations. The product sales region targets Russia and the Commonwealth of Independent States (CIS).

Isu Abxis's 'Pavagal' is a treatment for the rare disease Fabry disease and received product approval from the Ministry of Food and Drug Safety in 2014, after which sales began.